-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is a progressive neurodegenerative disease with insidious onset, commonly known as Alzheimer's disease
.
According to data from the International Alzheimer's Association, every 3 seconds, one AD patient worldwide develops
.
There are at least 300,000 new cases in China each year.
The current number of patients has exceeded 10 million, accounting for a quarter of the world's total population of AD patients, and this number is still rising with the aging of the population
.
It is estimated that by 2050, the number of Alzheimer's patients in the world will increase to more than 150 million
.
A few months ago, the world's first new Alzheimer's drug Aduhelm was approved for marketing.
However, due to its controversial efficacy, many well-known hospitals in the United States have publicly stated that they will not use it
.
The field of Alzheimer's treatment has returned to bleak again
.
In the past 20 years, countless drug trials have tried to find a cure to prevent the progression of Alzheimer's disease, but they have all failed
.
Several large pharmaceutical companies have therefore completely abandoned the goal of developing treatments for Alzheimer's disease
.
For patients, the only hope is that there will be a drug that can alleviate the symptoms of diseases including memory loss, insomnia, loss of speech or reasoning in a limited time
.
Now, the dawn of this field is reappearing! Recently, the Brigham and Women's Hospital affiliated to Harvard Medical School announced that it will take the lead in conducting the first human clinical trial of Alzheimer's disease vaccine, aiming to evaluate a nasal spray immunotherapy candidate drug called Protollin to prevent or slow down the disease Effectiveness of progress
.
The vaccine was developed by I-Mab
.
Previously, Dr.
Zang Jingwu, founder and chairman of Tianjing Biotech, said: “The introduction of Protollin to the clinic is an important milestone in the development of new treatments for this devastating disease.
We are honored to be able to participate in the planning process with our global partners.
Contribute our expertise
.
"It is reported that the phase I clinical trial is relatively small, and 16 patients with Alzheimer's disease between the ages of 60 and 85 will receive two intranasal administrations within a week
.
As we all know, the presence of abnormal β-amyloid and tau tangles in the brain are two typical characteristics of Alzheimer’s disease.
These sticky proteins cause the communication between nerve cells to be interrupted, and ultimately destroy the patient’s thinking or recall of information.
Ability
.
Therefore, treatments that prevent or reduce β-amyloid plaques and subsequent tau tangles may help prevent disease progression
.
Protollin is a new immunomodulator, this method is based on nearly 25 years of research by Howard Weiner's team, co-director of the An Romney Center for Neurological Diseases at Brigham and Women's Hospital
.
Protollin is made of protein extracted from the outer membrane of bacteria
.
It works by activating monocytes in the lymph nodes of the neck.
These monocytes migrate to the brain and trigger macrophages to clear beta-amyloid plaques and tau tangles
.
In order to activate the immune system without causing encephalitis, just as other research teams chose more traditional amyloid-based vaccines, Weiner's team eventually turned to Protollin alone, without injecting or causing the production of anti-amyloid antibodies
.
Weiner once said that if Protollin is effective, it will be a non-toxic treatment for patients with Alzheimer's disease, and it can also help people at high risk of Alzheimer's disease prevent disease.
.
Previous preclinical studies on Protollin showed that intranasal administration activated a type of brain immune cell called microglia and prevented the accumulation of β-amyloid plaques in young mice
.
In addition, in an elderly mouse model of Alzheimer's disease, this immunotherapy candidate drug reduced the accumulation of β-amyloid and improved the animal's memory function
.
The researchers said that their goal this time is to determine the safety and tolerability of the nasal vaccine in the trial, and to observe how Protollin affects the immune response of participants, including how it affects their white blood cells
.
Weiner added: "The immune system plays a very important role in all neurological diseases
.
What is exciting is that after more than two decades of pre-clinical work, we can finally take a critical step towards clinical transformation.
This landmark first human trial
.
Incredible! Scientists reversed the "permanent" brain damage in animals overnight, and restored the old brain to a young state.
.
.
.
According to data from the International Alzheimer's Association, every 3 seconds, one AD patient worldwide develops
.
There are at least 300,000 new cases in China each year.
The current number of patients has exceeded 10 million, accounting for a quarter of the world's total population of AD patients, and this number is still rising with the aging of the population
.
It is estimated that by 2050, the number of Alzheimer's patients in the world will increase to more than 150 million
.
A few months ago, the world's first new Alzheimer's drug Aduhelm was approved for marketing.
However, due to its controversial efficacy, many well-known hospitals in the United States have publicly stated that they will not use it
.
The field of Alzheimer's treatment has returned to bleak again
.
In the past 20 years, countless drug trials have tried to find a cure to prevent the progression of Alzheimer's disease, but they have all failed
.
Several large pharmaceutical companies have therefore completely abandoned the goal of developing treatments for Alzheimer's disease
.
For patients, the only hope is that there will be a drug that can alleviate the symptoms of diseases including memory loss, insomnia, loss of speech or reasoning in a limited time
.
Now, the dawn of this field is reappearing! Recently, the Brigham and Women's Hospital affiliated to Harvard Medical School announced that it will take the lead in conducting the first human clinical trial of Alzheimer's disease vaccine, aiming to evaluate a nasal spray immunotherapy candidate drug called Protollin to prevent or slow down the disease Effectiveness of progress
.
The vaccine was developed by I-Mab
.
Previously, Dr.
Zang Jingwu, founder and chairman of Tianjing Biotech, said: “The introduction of Protollin to the clinic is an important milestone in the development of new treatments for this devastating disease.
We are honored to be able to participate in the planning process with our global partners.
Contribute our expertise
.
"It is reported that the phase I clinical trial is relatively small, and 16 patients with Alzheimer's disease between the ages of 60 and 85 will receive two intranasal administrations within a week
.
As we all know, the presence of abnormal β-amyloid and tau tangles in the brain are two typical characteristics of Alzheimer’s disease.
These sticky proteins cause the communication between nerve cells to be interrupted, and ultimately destroy the patient’s thinking or recall of information.
Ability
.
Therefore, treatments that prevent or reduce β-amyloid plaques and subsequent tau tangles may help prevent disease progression
.
Protollin is a new immunomodulator, this method is based on nearly 25 years of research by Howard Weiner's team, co-director of the An Romney Center for Neurological Diseases at Brigham and Women's Hospital
.
Protollin is made of protein extracted from the outer membrane of bacteria
.
It works by activating monocytes in the lymph nodes of the neck.
These monocytes migrate to the brain and trigger macrophages to clear beta-amyloid plaques and tau tangles
.
In order to activate the immune system without causing encephalitis, just as other research teams chose more traditional amyloid-based vaccines, Weiner's team eventually turned to Protollin alone, without injecting or causing the production of anti-amyloid antibodies
.
Weiner once said that if Protollin is effective, it will be a non-toxic treatment for patients with Alzheimer's disease, and it can also help people at high risk of Alzheimer's disease prevent disease.
.
Previous preclinical studies on Protollin showed that intranasal administration activated a type of brain immune cell called microglia and prevented the accumulation of β-amyloid plaques in young mice
.
In addition, in an elderly mouse model of Alzheimer's disease, this immunotherapy candidate drug reduced the accumulation of β-amyloid and improved the animal's memory function
.
The researchers said that their goal this time is to determine the safety and tolerability of the nasal vaccine in the trial, and to observe how Protollin affects the immune response of participants, including how it affects their white blood cells
.
Weiner added: "The immune system plays a very important role in all neurological diseases
.
What is exciting is that after more than two decades of pre-clinical work, we can finally take a critical step towards clinical transformation.
This landmark first human trial
.
Incredible! Scientists reversed the "permanent" brain damage in animals overnight, and restored the old brain to a young state.
.
.
